Clinical trial NCT02763384: BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Official title: A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: T-Acute Lymphoblastic Leukemia
Adult T Lymphoblastic Lymphoma
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: The Leukemia and Lymphoma Society
name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2016-05-05
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The outcome of patients with relapsed or refractory adult T-acute lymphoblastic leukemia (T-ALL) and the related disease T-lymphoblastic lymphoma (T-LBL) is extremely poor with 30% of the patients responding to first salvage therapy and long-term survival of only 10%. Therefore, novel therapies for patients with relapsed/refractory T-ALL/LBL represent an unmet clinical need.

Recent data provide strong evidence that CXCR4 signaling plays a major role in T-cell leukemia cell maintenance and leukemia initiating activity, and targeting CXCR4 signaling in T-ALL cells reduces tumor growth in an animal model. In this study, the investigators propose that the addition of BL-8040 to nelarabine as a salvage therapy for patients with relapsed/refractory T-ALL/LBL will result in a higher complete remission (CR) rate than nelarabine alone without an increase in toxicity and will allow patients to proceed to a potentially curative allogeneic hematopoietic cell transplant.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of T-acute lymphoblastic leukemia/ lymphoblastic lymphoma according to WHO criteria which has relapsed or is refractory to chemotherapy.
* Peripheral blood lymphoblasts ≤ 50,000 mcL. Hydroxyurea and/or leukapheresis is permitted to reduce the peripheral blast count prior to enrollment and treatment.
* Age ≥ 18 years
* ECOG performance status ≤ 2.
* Adequate organ function defined as:

  * Calculated creatinine clearance ≥ 50 ml/min using the Cockroft-Gault formula
  * AST, ALT, total bilirubin ≤ 2 x institutional ULN except for Gilbert's disease or when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia), in which case ALT and AST may be elevated up to ≤ 5 x IULN.
* Women of childbearing potential and men must agree to use adequate contraception with a highly effective method (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Abstinence is acceptable if this is the established and preferred contraception for the subject.
* Female subjects must have a negative urine or serum pregnancy test within 72 hours prior to start of study treatment if of childbearing potential or be of non-childbearing potential. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as:

  \*≥ 45 years of age and has not had menses for \> 2 years
  * Amenorrheic for \> 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation
  * Post-hysterectomy, oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.
* Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

* Previous treatment with nelarabine for relapsed or refractory disease.
* Pregnant or nursing.
* Received any other investigational agent or systemic cytotoxic chemotherapy within the preceding 2 weeks.
* Active CNS involvement with leukemia
* Active HIV or hepatitis B or C infection.
* Any medical condition which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient. Subjects with a clinically significant or unstable medical or surgical condition or any other condition that cannot be well-controlled by the allowed medications permitted in the study protocol that would preclude safe and complete study participation, as determined by medical history, physical examinations, laboratory tests, and according to the investigator's judgment.

Primary outcomes:
measure: Safety and Tolerability of Regimen as Measured by Number of Participants With Adverse Events
timeFrame: Up to 30 days after completion of treatment (median follow-up of 51.5 days, full range 24-120 days)
Secondary outcomes:
measure: Composite Complete Remission Rate (CRc=CR+CRi)
timeFrame: Completion of treatment (approximately 12 weeks)
measure: Overall Response Rate (CR, CRi + PR)
timeFrame: Through completion of treatment (median treatment length of 37.5 days, full range of 13-90 days)
measure: Time to Response
timeFrame: Through completion of treatment (median treatment length of 37.5 days, full range of 13-90 days)
measure: Duration of Response
timeFrame: Through date of recurrence or completion of follow-up (maximum of 2 years after completion of treatment)
measure: Event-free Survival (EFS)
timeFrame: Through completion of follow-up (maximum of 2 years after completion of treatment)
measure: Overall Survival
timeFrame: Through completion of follow-up (maximum of 2 years after completion of treatment)
measure: Rate of Patients Who Proceed to alloHCT After Treatment
timeFrame: Through completion of treatment (median treatment length of 37.5 days, full range of 13-90 days)
Other outcomes:
measure: Interaction of Pretreatment Disease and White Blood Cell Count on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Interaction of Pretreatment Disease and Performance Status on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Interaction of Pretreatment Disease and Immunophenotype on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Interaction of Pretreatment Disease and Cytogenetics on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Interaction of Pretreatment Disease and CXCR4 Expression on Lymphoblasts on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Interaction of Pretreatment Disease and Morphology on Clinical Outcome
timeFrame: Up to 2 years after completion of treatment (approximately 116 weeks)
measure: Pharmacodynamic Effects of BL-8040 on T-lymphoblasts as Measured by Alterations in Lymphoblast Cell Cycle Status
timeFrame: Completion of treatment (approximately 12 weeks)
measure: Pharmacodynamic Effects of BL-8040 on T-lymphoblasts as Measured by Induction of Apoptosis in Lymphoblasts
timeFrame: Completion of treatment (approximately 12 weeks)
measure: Pharmacodynamic Effects of BL-8040 on T-lymphoblasts as Measured by Mobilization of Lymphoblasts Into the Peripheral Circulation
timeFrame: Completion of treatment (approximately 12 weeks)
measure: Pharmacodynamic Effects of BL-8040 on T-lymphoblasts as Measured by Inhibition of CXCR4 Signaling on Lymphoblasts
timeFrame: Completion of treatment (approximately 12 weeks)
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Washington University School of Medicine
name: Geoffrey L Uy, M.D.
role: PRINCIPAL_INVESTIGATOR
References: